Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

181. Association between diabetes mellitus and risk of new or recurrent heart failure

Association between diabetes mellitus and risk of new or recurrent heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

182. A systematic review and meta-analysis of vitamin D supplementation in the treatment of chronic heart failure

A systematic review and meta-analysis of vitamin D supplementation in the treatment of chronic heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2019 PROSPERO

183. A systematic review and meta-analysis of Coenzyme Q10 in reducing mortality in patients with chronic heart failure

A systematic review and meta-analysis of Coenzyme Q10 in reducing mortality in patients with chronic heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

184. A systematic review of maternal risk factors and biomarkers of heart failure during pregnancy

A systematic review of maternal risk factors and biomarkers of heart failure during pregnancy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2019 PROSPERO

185. Prognostic impact of pharmacological strategies for heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis

Prognostic impact of pharmacological strategies for heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

186. Red cell distribution width and mortality of heart failure: dose-response meta-analysis of prospective cohort studies

Red cell distribution width and mortality of heart failure: dose-response meta-analysis of prospective cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

187. The efficacy and safety of sacubitril/valsartan in the treatment of patients with heart failure with reduced left ventricular ejection fraction: a systematic review and meta-analysis

The efficacy and safety of sacubitril/valsartan in the treatment of patients with heart failure with reduced left ventricular ejection fraction: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

188. General medicine: Angiotensin receptor neprilysin inhibitors in older patients with heart failure

General medicine: Angiotensin receptor neprilysin inhibitors in older patients with heart failure Angiotensin receptor neprilysin inhibitors in older patients with heart failure | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? You are here Angiotensin receptor neprilysin inhibitors in older patients with heart failure Article Text EBM opinion and debate General medicine Angiotensin receptor neprilysin inhibitors in older patients with heart failure Anthony T Sharkey 1 , Mohd Zaquan Ghafar 1 , Shaun T O’Keeffe 1 , Eamon C Mulkerrin 1 , 2 Statistics from Altmetric.com Introduction Heart failure affects approximately 1.5% of the adult population in developed

2019 Evidence-Based Medicine

189. Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. Full Text available with Trip Pro

Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. The Hospital Readmissions Reduction Program (HRRP) has been associated with a reduction in readmission rates for heart failure (HF), acute myocardial infarction (AMI), and pneumonia. It is unclear whether the HRRP has been associated with change in patient mortality.To determine whether the HRRP was associated

2018 JAMA

190. Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials. (Abstract)

Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials. Atrial fibrillation (AF) and heart failure (HF) frequently coexist and are associated with increased morbidity and mortality risk.To compare benefits and harms between catheter ablation and drug therapy in adult patients with AF and HF.ClinicalTrials.gov, PubMed, Web of Science (Clarivate Analytics), EBSCO Information Services, Cochrane Central Register of Controlled Trials (...) %; risk ratio [RR], 0.52 [95% CI, 0.33 to 0.81) and HF hospitalizations (16.4% vs. 27.6%; RR, 0.60 [CI, 0.39 to 0.93]). Ablation improved left ventricular ejection fraction (LVEF) (mean difference, 6.95% [CI, 3.0% to 10.9%]), 6-minute walk test distance (mean difference, 20.93 m [CI, 5.91 to 35.95 m]), peak oxygen consumption (Vo2max) (mean difference, 3.17 mL/kg per minute [CI, 1.26 to 5.07 mL/kg per minute]), and quality of life (mean difference in Minnesota Living with Heart Failure Questionnaire

2018 Annals of Internal Medicine

191. Specialist nurses can manage heart failure drug dosing successfully

Specialist nurses can manage heart failure drug dosing successfully Specialist nurses can manage heart failure drug dosing successfully Discover Portal Discover Portal Specialist nurses can manage heart failure drug dosing successfully Published on 9 February 2016 doi: Use of specialist nurses to optimise drug dosages using protocols in people with heart failure was more effective than dose monitoring by other health professionals. These nurses had advanced practice certification. This finding (...) came from a review of seven trials with more than 1600 patients. International guidelines recommend two or three first-line medications for people with heart failure. These drugs (beta-adrenergic blocking agents, angiotensin converting enzyme inhibitors and angiotensin receptor blockers) can improve survival and are usually started at low doses by cardiologists and then gradually increased over time, a process managed between cardiologists and GPs. This can be a prolonged process because outpatient

2018 NIHR Dissemination Centre

192. Telehealth can help people with heart failure avoid hospital admission

Telehealth can help people with heart failure avoid hospital admission Telehealth can help people with heart failure avoid hospital admission Discover Portal Discover Portal Telehealth can help people with heart failure avoid hospital admission Published on 18 January 2016 doi: Home telephone or telemonitoring support can bring some aspects of specialised care and monitoring into the homes of people with heart failure. This updated Cochrane review confirmed that people with heart failure who (...) received home telehealth support were less likely to die or go into hospital for problems relating to their heart failure than those getting usual care. Usual care involved visiting a GP surgery or hospital for care and monitoring, which may be difficult for frail people with limited mobility. The review included seventeen new trials since the last review was published five years ago. More evidence is needed on which people would gain most benefit, particularly considering that people with heart

2018 NIHR Dissemination Centre

193. Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. Full Text available with Trip Pro

Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. Data are lacking on the effect of a renin-angiotensin system (RAS) inhibitor prescribed after transcatheter aortic valve replacement (TAVR). Treatment with a RAS inhibitor may reverse left ventricular remodeling and improve function.To investigate the association of prescription of a RAS inhibitor and outcomes after TAVR.Retrospective cohort (...) outcomes were all-cause death and readmission due to heart failure at 1 year after discharge, which were considered separately. The secondary outcome was health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ; score range: 0-100, with a higher score indicating less symptom burden and better quality of life; a small effect size was defined as 5 points) at 1 year.Among 21 312 patients who underwent TAVR at 417 US sites, 8468 patients (39.7%) were prescribed a RAS inhibitor

2018 JAMA

194. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure Full Text available with Trip Pro

Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial prospectively compared the efficacy of an N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided heart failure treatment strategy (target NT-proBNP level <1,000 pg/ml) with optimal medical therapy alone in high-risk patients with heart failure and reduced ejection fraction. When the study (...) $5,919 higher in the biomarker-guided strategy (95% CI: -$1,795, +$13,602) over 15-month median follow-up.A strategy of NT-proBNP-guided HF therapy had higher total costs and was not more effective than usual care in improving QOL outcomes in patients with heart failure and a reduced ejection fraction. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).Copyright © 2018 American College of Cardiology Foundation. All rights reserved.

2018 EvidenceUpdates

195. Chronic Heart Failure and Exercise Rehabilitation: A Systematic Review and Meta-Analysis (Abstract)

Chronic Heart Failure and Exercise Rehabilitation: A Systematic Review and Meta-Analysis The aim of this systematic review was to identify the effect of specific exercise parameters on physical function and quality of life (QOL) in people with chronic heart failure living in the community.A total of 5 electronic databases were searched for relevant studies published after 1994.The screening process was completed by 2 independent researchers, with a third independent reviewer for conflict (...) -regression, including 27 randomized control trials and 13 cohort studies. Exercise was shown to have a positive effect on QOL outcomes (standardized mean difference 1.16; 95% confidence interval [CI], 0.76-1.56) with the most commonly used measure, the Minnesota Living with Heart Failure Questionnaire, showing a clinically significant change of 8.5 points. Physical function was improved postexercise intervention in the 23 included studies (standardized mean difference 0.89; 95% CI, 0.40-1.38

2018 EvidenceUpdates

196. Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months and is hard to take for people with severe chronic heart failure

Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months and is hard to take for people with severe chronic heart failure Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months and is hard to take for people with severe chronic heart failure Discover Portal Discover Portal Home oxygen therapy prescribed for 15 hours a day did not reduce breathlessness at six months and is hard to take for people with severe chronic (...) heart failure Published on 7 January 2016 doi: This NIHR-funded trial found no evidence that long-term home oxygen therapy improves symptoms or quality of life for people with severe chronic heart failure. There were encouraging signs after three months but these were not sustained at six months by which time there was no difference between the oxygen therapy group, who continued to receive best medical care, and the control group. The trial was stopped early due to poor adherence to the therapy

2018 NIHR Dissemination Centre

197. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. Full Text available with Trip Pro

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown.We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites (...) . -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups.Among patients with heart failure with reduced ejection

2018 NEJM Controlled trial quality: predicted high

198. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Full Text available with Trip Pro

Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered often ask whether their medications can be stopped. The safety of withdrawing treatment in this situation is unknown.We did an open-label, pilot, randomised trial to examine the effect of phased withdrawal of heart failure medications in patients (...) ) to phased withdrawal or continuation of treatment. After 6 months, patients in the continued treatment group had treatment withdrawn by the same method. The primary endpoint was a relapse of dilated cardiomyopathy within 6 months, defined by a reduction in LVEF of more than 10% and to less than 50%, an increase in LVEDV by more than 10% and to higher than the normal range, a two-fold rise in NT-pro-BNP concentration and to more than 400 ng/L, or clinical evidence of heart failure, at which point

2018 Lancet Controlled trial quality: predicted high

199. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. There are few effective treatments for heart failure with preserved ejection fraction (HFpEF). Short-term administration of inorganic nitrite or nitrate preparations has been shown to enhance nitric oxide signaling, which may improve aerobic capacity in HFpEF.To determine the effect of 4 weeks' administration of inhaled (...) /mL; difference, 11 [95% CI, -53 to 75]; P = .74). Worsening heart failure occurred in 3 participants (2.9%) during the nitrite phase and 8 (7.6%) during the placebo phase.Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity.ClinicalTrials.gov Identifier: NCT02742129.

2018 JAMA Controlled trial quality: predicted high

200. CardioMEMS for Heart Failure Monitoring

CardioMEMS for Heart Failure Monitoring Health Evidence Review Commission (HERC) Coverage Guidance: CardioMEMS™ for Heart Failure Monitoring Approved 10/4/2018 HERC Coverage Guidance CardioMEMS™ is not recommended for coverage for heart failure monitoring (weak recommendation). Note: Definitions for strength of recommendation are in Appendix A. GRADE Table Element Descriptions. Rationales for each recommendation appear below in the GRADE table. 2 ¦ CardioMEMS™ for Heart Failure Monitoring (...) Approved 10/4/2018 Table of Contents Coverage Guidance: CardioMEMS™ for Heart Failure Monitoring 1 Table of Contents 2 Rationale for development of coverage guidances and multisector intervention reports 3 GRADE Table 3 GRADE Table 5 Should CardioMEMS™ be recommended for coverage for heart failure monitoring? 5 Background 8 Indications 8 Technology Description 8 Evidence Review 9 Abraham et al., 2011 9 Adamson et al., 2014 11 Adamson et al., 2016 12 Abraham et al., 2016 13 Givertz et al., 2017 15

2018 Oregon Health Evidence Review Commission